Sirolimus
Top View
- Retrospective Study of Sirolimus and Cyclophosphamide in Patients With
- Sirolimus-Erlotinib Protocol FINAL
- Long-Term Follow-Up of a Single Institution Pilot Study of Sirolimus
- RAPAMUNE (Sirolimus) ORAL SOLUTION and TABLETS Rapamune Following Cyclosporine Withdrawal: 2-4 Months Post- Transplantation, Withdraw Csa Over 4-8 Weeks (2.2)
- PRODUCT MONOGRAPH Pr RAPAMUNE®
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
- Rapalogs in Viral Cancers
- Medication Guidelines for Solid Organ Transplants
- Rapamune® (Sirolimus) Oral Solution and Tablets Rx Only WARNING
- RESEARCH HIGHLIGHTS Spironolactone and Hyperkalemia
- Influence of Drug Incorporation on the Physico-Chemical Properties Of
- Aps2017115.Pdf
- A Randomized Phase II Trial of Tacrolimus, Mycophenolate Mofetil and Sirolimus After Non-Myeloablative Unrelated Donor Transplantation
- Potential Herb-Drug Interactions Chart
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Thalidomide Is Better Than Rapamycin in Prevention of Neovascularization
- VUMC Automated Dispensing Cabinets
- Outcomes of Sirolimus Regimens in 65-Year-Old and Older Kidney Transplant Recipients: a Registry-Based Observational Study